在中国使用异武康唑、泊沙康唑和伏立康唑治疗侵袭性曲霉菌病的经济评估。

IF 2.5 4区生物学 Q3 MICROBIOLOGY

Future microbiology Pub Date : 2024-11-18 DOI:10.1080/17460913.2024.2423530

Qiang Liu, Pingyu Chen, Dunming Xiao, Jingxuan Wei, Yintao Lin, Tiantian Tao, Xin Li

{"title":"在中国使用异武康唑、泊沙康唑和伏立康唑治疗侵袭性曲霉菌病的经济评估。","authors":"Qiang Liu, Pingyu Chen, Dunming Xiao, Jingxuan Wei, Yintao Lin, Tiantian Tao, Xin Li","doi":"10.1080/17460913.2024.2423530","DOIUrl":null,"url":null,"abstract":"Aim: To assess the cost-effectiveness of treating invasive aspergillosis with isavuconazole, posaconazole and voriconazole in China.Materials & methods: A cost-consequence analysis (CCA) was conducted, considering both healthcare system and patient out-of-pocket perspectives. We considered the costs of medications, diagnostics and hospitalization and the consequences of mortality, response rate and adverse events.Results: From the healthcare system perspective, compared with voriconazole, isavuconazole saved 967.39 Chinese Yuan (CNY) and posaconazole saved 8624.82 CNY. From the patient out-of-pocket perspective, compared with voriconazole, isavuconazole saved 1056.00 CNY, posaconazole increased 3153.83 CNY. The CCA demonstrated that isavuconazole exhibited higher medical costs but lower out-of-pocket costs compared with posaconazole, while there were no significant differences in consequences.Conclusion: Isavuconazole is potentially the most economical option.","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"1-13"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Economic evaluation of treating invasive aspergillosis with isavuconazole, posaconazole and voriconazole in China.\",\"authors\":\"Qiang Liu, Pingyu Chen, Dunming Xiao, Jingxuan Wei, Yintao Lin, Tiantian Tao, Xin Li\",\"doi\":\"10.1080/17460913.2024.2423530\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: To assess the cost-effectiveness of treating invasive aspergillosis with isavuconazole, posaconazole and voriconazole in China.Materials & methods: A cost-consequence analysis (CCA) was conducted, considering both healthcare system and patient out-of-pocket perspectives. We considered the costs of medications, diagnostics and hospitalization and the consequences of mortality, response rate and adverse events.Results: From the healthcare system perspective, compared with voriconazole, isavuconazole saved 967.39 Chinese Yuan (CNY) and posaconazole saved 8624.82 CNY. From the patient out-of-pocket perspective, compared with voriconazole, isavuconazole saved 1056.00 CNY, posaconazole increased 3153.83 CNY. The CCA demonstrated that isavuconazole exhibited higher medical costs but lower out-of-pocket costs compared with posaconazole, while there were no significant differences in consequences.Conclusion: Isavuconazole is potentially the most economical option.\",\"PeriodicalId\":12773,\"journal\":{\"name\":\"Future microbiology\",\"volume\":\" \",\"pages\":\"1-13\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-11-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future microbiology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1080/17460913.2024.2423530\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1080/17460913.2024.2423530","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：评估在中国使用异武康唑、泊沙康唑和伏立康唑治疗侵袭性曲霉菌病的成本效益：我们从医疗系统和患者自付费用两个角度进行了成本-后果分析（CCA）。我们考虑了药物、诊断和住院的成本，以及死亡率、应答率和不良事件的后果：结果：从医疗系统角度来看，与伏立康唑相比，异武康唑节省了 967.39 元人民币，泊沙康唑节省了 8624.82 元人民币。从患者自费角度看，与伏立康唑相比，异武康唑节省了 1056.00 元人民币，泊沙康唑增加了 3153.83 元人民币。CCA显示，与泊沙康唑相比，伊沙武康唑的医疗费用较高，但自付费用较低，而在后果方面没有显著差异：结论：异武康唑可能是最经济的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Economic evaluation of treating invasive aspergillosis with isavuconazole, posaconazole and voriconazole in China.

Aim: To assess the cost-effectiveness of treating invasive aspergillosis with isavuconazole, posaconazole and voriconazole in China.Materials & methods: A cost-consequence analysis (CCA) was conducted, considering both healthcare system and patient out-of-pocket perspectives. We considered the costs of medications, diagnostics and hospitalization and the consequences of mortality, response rate and adverse events.Results: From the healthcare system perspective, compared with voriconazole, isavuconazole saved 967.39 Chinese Yuan (CNY) and posaconazole saved 8624.82 CNY. From the patient out-of-pocket perspective, compared with voriconazole, isavuconazole saved 1056.00 CNY, posaconazole increased 3153.83 CNY. The CCA demonstrated that isavuconazole exhibited higher medical costs but lower out-of-pocket costs compared with posaconazole, while there were no significant differences in consequences.Conclusion: Isavuconazole is potentially the most economical option.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future microbiology 生物-微生物学

CiteScore

4.90

自引率

3.20%

发文量

134

审稿时长

6-12 weeks

期刊介绍： Future Microbiology delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this increasingly important and vast area of research.